Abstract: Methods and compositions for treating a coronavirus infection in a subject are provided. Also provided are methods and compositions for preventing or treating a coronavirus-associated disease in a subject. The methods and compositions include administering a pharmaceutical composition containing an effective amount of a caspase-6 inhibitor to a subject. The amount of the caspase-6 inhibitor contained in the pharmaceutical composition is effective to reduce replication of the coronavirus in the subject. The disclosed methods and compositions ameliorate lung pathology associated with the coronavirus infection and increases survival in the subject.

Abstract: The invention relates to the field of biomedicine. In particular, the invention relates to a live strain of Staphylococcus aureus and uses thereof. More particularly, the invention relates to a live strain of Staphylococcus aureus which lacks adenosine synthase A (AdsA) activity, to a vaccine against Staphylococcus aureus infection comprising said live strain, and a method for preventing and/or treating Staphylococcus aureus infection in a subject by administering said live strain.

Abstract: The invention relates to the technical field of medicine, and provides a method of screening and identifying small molecule with antiviral properties. The invention has screened and identified Cannabidiol (CBD), which can be used for prevention of viral infections. The invention also examined and verified that CBD can be used for prevention of COVID-19 disease, by a key signaling pathway of upregulating the expression of the TRIB3 gene. The invention also determined that the optimal dosage of CBD treatment for prevention of COVID-19 disease is 5 ?M-10 ?M.

Abstract: AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-? signaling, and is not a result of activation of the hosts innate immune response.